Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1-3 clinical trials

Hirano, I., Dellon, E. S., Gupta, S. K., Katzka, D. A., Collins, M. H., Wojtowicz, A. M., Terreri, B., Zhang, W., Boules, M., Bhatia, S., & Desai, N. K. (2023). Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials. Alimentary Pharmacology & Therapeutics, 57(10), 1117–1130. Portico. https://doi.org/10.1111/apt.17430
Authors:
Ikuo Hirano
Evan S Dellon
Sandeep K Gupta
David A Katzka
Margaret H Collins
Abigail M Wojtowicz
Brian Terreri
Wenwen Zhang
Mena Boules
Siddharth Bhatia
Nirav K Desai
Affiliated Authors:
David A Katzka
Columbia Affiliation:
Subjects:
Diagnosis and Management of Eosinophilic Esophagitis (OpenAlex Topic)
Hypereosinophilic Syndrome and Related Disorders (OpenAlex Topic)
Esophageal Intervention Techniques (OpenAlex Topic)
Budesonide (MeSH)
Eosinophilic Esophagitis (MeSH)
Author Keywords:
adverse event
eosinophilic esophagitis
exposure-adjusted incidence rate
oesophageal eosinophilia
safety integration
swallowed topical corticosteroid
elink
Publication Type:
Article
Unique ID:
10.1111/apt.17430
PMID:
36890134
DOI:
10.1111/apt.17430
Journal:
Alimentary Pharmacology and Therapeutics
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View OpenAlex Record

Record Created: